Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile

Cancer Biology and Therapy

Volumn 11, Issue 4, 2011, Pages 373-382

  Garrido, Greta ^a   Tikhomirov, Ilia A ^c   Rabasa, Ailem ^a   Yang, Eric ^d   Gracia, Elias ^b   Iznaga, Normando ^a   Fernández, Luis E ^a   Crombet, Tania ^a   Kerbel, Robert S ^d   Pérez, Rolando ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^c YM BioSciences Inc   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Affinity; Avidity; Cancer immunotherapy; EGFR; Monoclonal antibodies; Nimotuzumab; Tumor targeting

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; NIMOTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL SURVIVAL; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, SCID; NEOPLASMS; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951826933     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.4.14097     Document Type: Article

References (60)

1. Pal SK, Pegram M. Epidermal growth factor receptor and signal transduction: potential targets for anticancer therapy. Anticancer Drugs 2005; 16:483-94. (Pubitemid 40685732)
2. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158:1-9.
3. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol 2008; 47:9-19.
4. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646-54. (Pubitemid 41079803)
5. Rodriguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343-9.
6. Crombet T, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 2006; 5:375-9.
7. Bode U, Buchen S, Warmuth-Metz T, Pietsch F, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2007; 25.
8. Crombet T, Figueredo J, Salomón MT, Selva JC, Toledo C, Vaquer JE, et al. Use the humanized anti-EGFR MAb (nimotuzumab) and irradiation for the treatment of high grade glioma patients. Eur J Cancer Supp 2008; 6:168.
9. Macias A, Neninger E, Santiesteban E, Figueredo J, Hernandez A, Aguirre F, et al. Preliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases. Eur J Cancer Supp 2008; 6:160.
10. Soriano JL, Batista N, Lima M, Rodriguez R, López MV, Gonzalez J, et al. Phase I Clinical Study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally advanced breast cancer. Preliminary results. Eur J Cancer Supp 2007; 5:116.
11. Bebb G, Smith C, Rorke S, Boland W, Nicacio L, Sukhoo R, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol 2010; In press.
12. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther 2010; 48:473-5.
13. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-12. (Pubitemid 44450468)
14. Izzedine H, Bahleda R, Khayat D, Massard C, Magne N, Spano JP, et al. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 2010; 73:213-9.
15. Berlin J, Van Cutsem E, Peeters JR, Hecht R, Ruiz R, Wolf M, et al. Predective value of skin toxicity severity for response to panitumumab in patients with metastatic coloreactal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol 2007; 25:4134.
16. Orditura M, De Vita F, Galizia G, Lieto E, Vecchione L, Vitiello F, et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009; 21:1023-8.
17. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657-70. (Pubitemid 44436627)
18. Talavera A, Friemann R, Martínez C, Garrido G, Rabasa R, Lopez-Requena A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69:5851-9.
19. Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, et al. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008; 122:1530-8. (Pubitemid 351294961)
20. Lammerts van Bueren JJ, Bleeker WK, Brannstrom A, von Euler A, Jansson M, Peipp M, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008; 105:6109-14. (Pubitemid 351758407)
21. Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. Epidermal growth factor receptor (EGFR) antibody downregulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 2006; 281:40183-92. (Pubitemid 46041823)
22. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78. (Pubitemid 43209104)
23. Giro C, Berger B, Bolke E, Ciernik IF, Duprez F, Locati L, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009; 90:166-71.
24. Mateo C, Moreno E, Amour K, Lombardero J. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71-81. (Pubitemid 27197395)
25. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 1983; 80:1337-41. (Pubitemid 13082800)
26. Bergh J, Nilsson K, Ekman R, Giovanella B. Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. Acta Pathol Microbiol Immunol Scand 1985; 93:133-47. (Pubitemid 15061149)
27. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45:2913-23.
28. Eisinger M, Lee JS, Hefton JM, Darzynkiewicz Z, Chiao JW, de Harven E. Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements. Proc Natl Acad Sci USA 1979; 76:5340-4. (Pubitemid 10236137)
29. Säfsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem 2006; 353:181-90. (Pubitemid 43775424)
30. Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993; 157:233-40.
31. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
32. Haigler H, Ash JF, Singer SJ, Cohen S. Visualization by fluorescence of the binding and intemalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci USA 1978; 75:3317-21. (Pubitemid 8389718)
33. Suarez Pestana E, Greiser U, Sanchez B, Fernandez LE, Lage A, Perez R, et al. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 1997; 75:213-20. (Pubitemid 27019565)
34. 11C-PD153035. Chin Med J 2007; 120:960-4.
35. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726-31. (Pubitemid 16000351)
36. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1993; 53:4322-8. (Pubitemid 24146785)
37. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-101. (Pubitemid 32681540)
38. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75.
39. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9:1199-206.
40. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010; 16:2474-82.
41. Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008; 26:2779-80.
42. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-24. (Pubitemid 34032602)
43. Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163:303-12. (Pubitemid 36759615)
44. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478-86.
45. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28:1181-9.
46. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24:155-61.
47. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11. (Pubitemid 40544648)
48. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 2000; 60:7008-13. (Pubitemid 32059177)
49. Laux I, Jain A, Singh S, Agus DB. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 2006; 94:85-92. (Pubitemid 43088546)
50. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749-55. (Pubitemid 351272610)
51. Diaz A, Rolff J, Lemm M, Fitchner I, Perez R, Montero E. Radiosensitisation of U87MG brain tumors by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 2009; 100:950-8.
52. Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:918-27.
53. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31:1191-8. (Pubitemid 20213280)
54. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61:4750-5. (Pubitemid 32691886)
55. Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, et al. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry 2008; 47:2518-30. (Pubitemid 351304557)
56. Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JML, Wu Y, et al. Dose-dependent increases in circulating TGFalpha and other ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 2009; 15:2397-405.
57. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13. (Pubitemid 36331964)
58. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11. (Pubitemid 40544648)
59. Kang ES, Oh MA, Lee SA, Kim TY, Kim SH, Gotoh N, et al. EGFR phosphorylation-dependent formation of cell-cell contacts by Ras/Erks cascade inhibition. Biochim Biophys Acta 2007; 1773:833-43. (Pubitemid 46839139)
60. Forsberg S, Ostman A, Rollman O. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase. Arch Dermatol Res 2008; 300:505-16.